Stock comparison
Eli Lilly
Nektar Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
NKTR
Nektar Therapeutics
Market cap
$1.33B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | NKTR | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 37D | LLY |
| Benjamin Graham | 86A | 56D | LLY |
| Philip Fisher | 86A | 48D | LLY |
| Peter Lynch | 74B | 3F | LLY |
| Joel Greenblatt | 78C | 2F | LLY |
| Charlie Munger | 85A | 39D | LLY |
| Terry Smith | 77C | 43D | LLY |
Side-by-side metrics
| Metric | LLY | NKTR |
|---|---|---|
| Market cap | $1T | $1.33B |
| P/E (TTM) | 36.6x | - |
| EV/EBIT | 34.1x | - |
| ROIC (TTM) | 32.06% | -17.17% |
| Gross margin | 83.51% | 99.38% |
| Net margin | 34.98% | -2.84% |
| Revenue CAGR 5y | 23.17% | -14.2% |
| EPS CAGR 5y | 40.81% | - |
| Debt / Equity | 1.4x | 0.1x |
| Dividend yield | 0.62% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Revenue CAGR 5y23.17%vs -14.2%+161%
- ROIC (TTM)32.06%vs -17.17%+154%
- Net margin34.98%vs -2.84%+112%
- Dividend yield0.62%vs 0.0%+100%
NKTR leads on
- P/E (TTM)-vs 36.6x+133%
- EV/EBIT-vs 34.1x+133%
- Debt / Equity0.1xvs 1.4x+90%
- Gross margin99.38%vs 83.51%+16%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.